Pfizer Geodon CV Safety Trial Fully Enrolled; Rx Growth Slows
Pfizer has completed enrollment in a cardiovascular safety study of the antipsychotic Geodon (ziprasidone), the company told investors during an Oct. 17 conference call.
Pfizer has completed enrollment in a cardiovascular safety study of the antipsychotic Geodon (ziprasidone), the company told investors during an Oct. 17 conference call.